Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113347 | 0.90 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL16133722 | 0.89 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2841670 | 0.88 | CYP2C9 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2839016 | 0.88 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL17464357 | 0.87 | CYP3A4 (0.39) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2843686 | 0.87 | CYP2C9 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2843683 | 0.87 | CYP3A4 (0.47) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2835738 | 0.86 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2840278 | 0.86 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL16112805 | 0.86 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2970174-B1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
| EP-2970174-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | CYP2C9 253/4885CYP3A4 152/4885CYP2C19 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.